• Publications
  • Influence
Serum GFAP is a diagnostic marker for glioblastoma multiforme.
A serum marker for malignant cerebral astrocytomas could improve both differential diagnosis and clinical management of brain tumour patients. To evaluate whether the serum concentration of glialExpand
  • 155
  • 9
  • PDF
Functional impairment, disability, and quality of life outcome after decompressive hemicraniectomy in malignant middle cerebral artery infarction.
OBJECT Whether decompressive hemicraniectomy is an appropriate treatment for space-occupying middle cerebral artery (MCA) infarction is still a controversial issue. Previous studies are in agreementExpand
  • 120
  • 7
  • PDF
Serum glial fibrillary acidic protein as a biomarker for intracerebral haemorrhage in patients with acute stroke
Background: Biomarkers of stroke are an evolving field of clinical research. A serum marker which can differentiate between haemorrhagic and ischaemic stroke in the very early phase would help toExpand
  • 146
  • 6
Evaluation of serum S100B as a surrogate marker for long-term outcome and infarct volume in acute middle cerebral artery infarction.
BACKGROUND An easily accessible and valid surrogate marker for interventional stroke trials is needed. OBJECTIVE To investigate the usefulness of various S100B serum measures to predict long-termExpand
  • 148
  • 5
  • PDF
Elevated serum S100B levels indicate a higher risk of hemorrhagic transformation after thrombolytic therapy in acute stroke.
BACKGROUND AND PURPOSE Intracerebral hemorrhage constitutes an often fatal sequela of thrombolytic therapy in patients with ischemic stroke. Early blood-brain barrier disruption may play an importantExpand
  • 74
  • 5
Serum S100B Predicts a Malignant Course of Infarction in Patients With Acute Middle Cerebral Artery Occlusion
Background and Purpose— Early predictors of infarct volume may improve therapeutic decisions in patients with acute cerebral ischemia. We investigated whether measurements of serum astroglial proteinExpand
  • 143
  • 4
  • PDF
Plasma and Brain Matrix Metalloproteinase-9 After Acute Focal Cerebral Ischemia in Rats
Background and Purpose— Plasma levels of matrix metalloproteinase-9 (MMP-9) have been proposed to be a useful biomarker for assessing pathological events in brain. Here, we examined the temporalExpand
  • 104
  • 4
Experimental Model of Warfarin-Associated Intracerebral Hemorrhage
Background and Purpose— Future demographic changes predict an increase in the number of patients with atrial fibrillation. As long-term anticoagulation for the prevention of ischemic strokes becomesExpand
  • 91
  • 4
Pretreatment With Antiplatelet Agents Is Not Independently Associated With Unfavorable Outcome in Intracerebral Hemorrhage
Background and Purpose— This study investigated the effect of preexisting antiplatelet therapy on mortality and functional outcome in patients with intracerebral hemorrhage (ICH). Methods— OurExpand
  • 89
  • 4
Angiopoietin-2-induced blood–brain barrier compromise and increased stroke size are rescued by VE-PTP-dependent restoration of Tie2 signaling
The homeostasis of the central nervous system is maintained by the blood–brain barrier (BBB). Angiopoietins (Ang-1/Ang-2) act as antagonizing molecules to regulate angiogenesis, vascular stability,Expand
  • 57
  • 4